Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016
Published Jul 20, 2016
45 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016, provides an overview of the Nasopharyngitis (Common Cold) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
- The report reviews pipeline therapeutics for Nasopharyngitis (Common Cold) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nasopharyngitis (Common Cold) therapeutics and enlists all their major and minor projects
- The report assesses Nasopharyngitis (Common Cold) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devis

  
Source:
Document ID
GMDHC8250IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Nasopharyngitis (Common Cold) Overview61
Therapeutics Development72
  Pipeline Products for Nasopharyngitis (Common Cold) Overview71
  Pipeline Products for Nasopharyngitis (Common Cold) Comparative Analysis81
Nasopharyngitis (Common Cold) Therapeutics under Development by Companies91
Nasopharyngitis (Common Cold) Therapeutics under Investigation by Universities/Institutes101
Nasopharyngitis (Common Cold) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Nasopharyngitis (Common Cold) Products under Development by Companies131
Nasopharyngitis (Common Cold) Products under Investigation by Universities/Institutes141
Nasopharyngitis (Common Cold) Companies Involved in Therapeutics Development154
  Charleston Laboratories, Inc.151
  Cocrystal Pharma, Inc.161
  Orbis Biosciences Inc171
  Vernalis Plc181
Nasopharyngitis (Common Cold) Therapeutics Assessment1910
  Assessment by Monotherapy Products191
  Assessment by Combination Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Drug Profiles2910
  (levocetirizine dihydrochloride + montelukast sodium) Drug Profile291
  Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders Drug Profile301
  CCP-05 Drug Profile311
  CCP-06 Drug Profile321
  CCP-07 Drug Profile331
  CCP-08 Drug Profile341
  CLAT-313 Drug Profile351
  guaifenesin ER Drug Profile361
  Small Molecule to Inhibit MAPK13 for Asthma and Cold Drug Profile371
  Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold Drug Profile381
Nasopharyngitis (Common Cold) Dormant Projects391
Nasopharyngitis (Common Cold) Discontinued Products401
Nasopharyngitis (Common Cold) Product Development Milestones413
  Featured News &Press Releases411
    Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study411
    Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study411
    Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study411
    Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine421
    Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing421
    Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept431
Appendix442
  Methodology441
  Coverage441
  Secondary Research441
  Primary Research441
  Expert Panel Validation441
  Contact Us441
  Disclaimer451

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Nasopharyngitis-Common-Cold-Pipeline-Review-H2-2016-2088-16224>
  
APA:
Global Markets Direct - Market Research. (2016). Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Nasopharyngitis-Common-Cold-Pipeline-Review-H2-2016-2088-16224>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.